A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients

British Journal of Clinical Pharmacology

Volumn 80, Issue 1, 2015, Pages 101-109

  Hua, Fei ^a   Ribbing, Jakob ^a   Reinisch, Walter ^b   Cataldi, Fabio ^a   Martin, Steven ^a  

^a PFIZER INC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

anrukinzumab; asthma; healthy volunteers; IL13; IMA 638; monoclonal antibody; NONMEM; pharmacokinetics; population PK; ulcerative colitis

Indexed keywords

ANRUKINZUMAB; CALGRANULIN; ANRUKINZUMAB, HUMAN; MONOCLONAL ANTIBODY;

ABSORPTION RATE CONSTANT; ADULT; ARTICLE; ASTHMA; BODY WEIGHT; CLINICAL STUDY; COMPARTMENT MODEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; ULCERATIVE COLITIS; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; NORMAL HUMAN; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOLOGICAL AVAILABILITY; COLITIS, ULCERATIVE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84933045022     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12589     Document Type: Article

References (21)

1. Wynn TA,. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-56.
2. Neurath MF, Finotto S, Glimcher LH,. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002; 8: 567-73.
3. Kasaian MT, Miller DK,. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008; 76: 147-55.
4. McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014; 23: 183-98.
5. Muzes G, Molnar B, Tulassay Z, Sipos F,. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012; 18: 5848-61.
6. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W,. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-7.
7. Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan XY, Tchistiakova L,. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011; 187: 561-9.
8. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, Cook TA, Lee J, Widom A, Agostinelli R, Bree A, Schlerman FJ, Olland S, Wadanoli M, Sypek J, Gill D, Goldman SJ, Tchistiakova L,. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008; 325: 882-92.
9. Highlights of Prescribing Information-REMICADE. 2015; Available online at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/103772s5370lbl.pdf (last accessed 2 September 2015).
10. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-28.
11. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H,. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-95.
12. Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D,. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 2014; 78: 118-28.
13. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G,. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012; 73: 55-65.
14. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-59.
15. Rosario M, Dirks N, Gastonguay M, Fox I, Milton A,. P385. Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease Poster 9th Congress of the European Crohn's and Colitis Organisation. Copenhagen, Denmark 2014.
16. Roopenian DC, Akilesh S,. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-25.
17. Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL,. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol- Gastr L 2006; 290: G352-60.
18. Reinisch W, Panes J, Khurana S, Toth G, Hua F, Comer GM, Hinz M, Page K, O'Toole M, McDonnell Moorehead T, Zhu H, Sun Y, Cataldi F,. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 2015 January 7, DOI: 10.1136/gutjnl-2014-308337. [Epub ahead of print].
19. Ordas I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
20. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L,. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 704-7.
21. Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG,. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin 1992; 30: 197-202.